# Liquidia share price today (Liquidia Corporation, LQDA)

> Liquidia Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. LQDA · Healthcare · Drug Manufacturers - Specialty & Generic · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/lqda

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $42.20 (+73.2% in a year)
- P/E: 28.6×, against its own history
- Revenue (Jun 2026): ₹0.2 B (+1,842.7% on a year ago)
- Profit (Jun 2026): ₹0.1 B
- Operating margin: 49.8% (+474.2 points on a year ago)
- ROE: −154%, FY25

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Liquidia share price today? Liquidia Corporation's share price was $42.20 at the close on 3 November 2026. It has been moving sideways for 6 weeks. That is 22.3% below its average price over the last 200 trading days. In the last 52 weeks it traded between $26 and $90, and at that close it sat 25% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 9 weeks running. Over the last 8.3 years the share price moved +284% while the S&P 500 moved +168%, so it is ahead of the index over that whole period. It was last ahead over 13 weeks in the week of 4 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Liquidia pay? Liquidia Corporation pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Liquidia on? Liquidia is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Liquidia profitable? Liquidia Corporation earned ₹0.1 B of net profit in the Jun 2026 quarter. The full FY25 year was a loss of ₹0.1 B. That is 43.5% of the quarter's revenue. The same quarter a year earlier lost ₹0.04 B. 9 of the last 12 reported quarters were loss-making. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Liquidia make, and is it growing? Liquidia Corporation reported ₹0.2 B of revenue in the Jun 2026 quarter, +1,842.7% on the same quarter a year earlier. That is the 6th quarter in a row with growth on the year before. Over 4 years it has grown 87.3% a year on average. The last full year, FY25, came in at ₹0.2 B. The last four reported quarters add to ₹0.5 B. FY25 revenue was ₹0.2 B, +1,031.2% on the year before. Recent pace: the last four quarters grew +2,544.4% on average, against 87.3% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +2,233.6%, against +451.2% a year over the last 8 quarters (accelerating). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Liquidia keep? Liquidia Corporation's operating margin was 49.8% in the Jun 2026 quarter, 474.2 percentage points higher than the same quarter a year ago. Across 5 years it has been between −866.6% and −32.5%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +474.2 percentage points on the year while gross margin changed +10.2 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Liquidia's profit turning into cash? Liquidia Corporation's cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.0 B of cash, against −₹0.1 B of profit. After ₹0.0 B of spending on assets, free cash was ₹0.0 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Liquidia's cash go? Liquidia Corporation does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Liquidia's P/E ratio, and how does it compare with its own history? Liquidia Corporation's P/E is 28.6×, with too little history to compare. This compares the share price with the company’s own past. It does not say what the business is worth. In short: there is too little history to say whether the multiple is high or low for this company, so the earnings trend underneath matters more than the multiple. ## Is the Liquidia business getting better or worse? Liquidia Corporation's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Liquidia earn on its capital? Liquidia Corporation earned a ROE of −154% in FY25. That is up from a low of −166% in FY23. Its return on capital used (ROIC) is left out: on sales this small it reads −198%, a number that says nothing useful about the business. It comes from a −43.5% net margin and 0.48× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −43.5% net margin × 0.48× asset turnover × 7.33× leverage (assets divided by equity) ≈ −153.1% on equity. The margin does its share; borrowing is a big part of it. ## Does Liquidia have too much debt? Liquidia Corporation has total debt of ₹0.2 B against shareholder equity of ₹0.2 B as of Jun 2026, so its debt is 0.94× its equity. Year by year, that ratio went from 0.25 in FY21 to 4.42 in FY25. Keep that borrowing in mind when reading the returns on this page. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Liquidia shareholding pattern? 26.5% of Liquidia Corporation's tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 2.9 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Liquidia from balance-sheet trouble? For Liquidia Corporation, the Z-score is 6.79. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 6.79 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Liquidia rank in its industry? 54.1 out of 100, rank 11 of 28 in Drug Manufacturers - Specialty & Generic, with 64% of the evidence available. Liquidia Corporation scores 54.1 out of 100 against the 28 companies it is compared with in Drug Manufacturers - Specialty & Generic, ranking 11. Earnings are strong; relative strength in its sector is -27.2% and the one-year return is 61.7%. The four parts add up to the total exactly: 26 + 17.9 + 9.2 + 1 = 54.1. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Liquidia compared with? Liquidia ranks 11 of 28 Drug Manufacturers - Specialty & Generic companies on the 4-Factor Sector Score, with 54.1 out of 100. 1. [Neurocrine Biosciences, Inc.](https://www.sectoralpha.in/us/stocks/nbix) NBIX · turning · Most evidence points up · 81% evidence 66.6 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.8/35 · Revenue 34.4% · Profit 100% · Operating margin change 1 points · 83% evidence Capital efficiency 17.8/25 · ROCE 19.3% · Operating margin 22.2% · 76% evidence Valuation 13.8/20 · P/E 24× · PEG 0.71 · 65% evidence Relative strength 9.2/20 · Lead over its industry -4.9% · Lead over S&P 500 7% · 1 year 8.2% · 100% evidence · 0 of 12 weeks ahead Exact sum: 25.8 + 17.8 + 13.8 + 9.2 = 66.6 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 2. [Eton Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/eton) ETON · leader · Most evidence points up · 64% evidence 65.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 81% · Profit n/a · Operating margin change 37.2 points · 62% evidence Capital efficiency 17.6/25 · ROCE 29.2% · Operating margin 35.8% · 76% evidence Valuation 8.8/20 · P/E 78.2× · PEG n/a · 15% evidence Relative strength 14.0/20 · Lead over its industry 37.9% · Lead over S&P 500 52.3% · 1 year 201.5% · 100% evidence · 12 of 12 weeks ahead Exact sum: 25.3 + 17.6 + 8.8 + 14 = 65.7 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) INDV · quiet · Evidence leans up · 71% evidence 63.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.5/35 · Revenue 13.5% · Profit 100% · Operating margin change 23.4 points · 83% evidence Capital efficiency 20.8/25 · ROCE 152.3% · Operating margin 46.9% · 76% evidence Valuation 10.3/20 · P/E 14.1× · PEG n/a · 15% evidence Relative strength 4.9/20 · Lead over its industry -13% · Lead over S&P 500 -2.1% · 1 year 15.8% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.5 + 20.8 + 10.3 + 4.9 = 63.5 · What this means: Earnings are strong; relative strength in its sector is -13% and the one-year return is 15.8%. 4. [Kiniksa Pharmaceuticals International, plc](https://www.sectoralpha.in/us/stocks/knsa) KNSA · leader · Evidence leans up · 71% evidence 61.7 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 23.8/35 · Revenue 58.7% · Profit 100% · Operating margin change -1.7 points · 83% evidence Capital efficiency 11.9/25 · ROCE 13.8% · Operating margin 11.2% · 76% evidence Valuation 9.0/20 · P/E 61× · PEG n/a · 15% evidence Relative strength 17.0/20 · Lead over its industry 40.9% · Lead over S&P 500 56.9% · 1 year 143.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 23.8 + 11.9 + 9 + 17 = 61.7 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Xeris Biopharma Holdings, Inc.](https://www.sectoralpha.in/us/stocks/xers) XERS · leader · Evidence leans up · 64% evidence 59.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 20.7/35 · Revenue 36.2% · Profit n/a · Operating margin change -0.7 points · 62% evidence Capital efficiency 11.5/25 · ROCE 16.5% · Operating margin 5.6% · 76% evidence Valuation 8.7/20 · P/E 83.3× · PEG n/a · 15% evidence Relative strength 18.6/20 · Lead over its industry 18.4% · Lead over S&P 500 32.5% · 1 year 39.3% · 100% evidence · 12 of 12 weeks ahead Exact sum: 20.7 + 11.5 + 8.7 + 18.6 = 59.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) BHC · leader · Evidence leans up · 71% evidence 59.3 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 17.5/35 · Revenue 10.1% · Profit -1220.4% · Operating margin change 9.1 points · 83% evidence Capital efficiency 12.6/25 · ROCE 13.5% · Operating margin 27.2% · 76% evidence Valuation 10.9/20 · P/E -1.7× · PEG n/a · 15% evidence Relative strength 18.3/20 · Lead over its industry 15.4% · Lead over S&P 500 29.8% · 1 year 22.4% · 100% evidence · 12 of 12 weeks ahead Exact sum: 17.5 + 12.6 + 10.9 + 18.3 = 59.3 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [BioCryst Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/bcrx) BCRX · quiet · Evidence leans up · 64% evidence 58.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 25.3/35 · Revenue 68.5% · Profit n/a · Operating margin change 26.9 points · 62% evidence Capital efficiency 18.1/25 · ROCE 112% · Operating margin 45.1% · 76% evidence Valuation 11.0/20 · P/E -6.6× · PEG n/a · 15% evidence Relative strength 4.5/20 · Lead over its industry -13.8% · Lead over S&P 500 -3.2% · 1 year 20.9% · 100% evidence · 3 of 12 weeks ahead Exact sum: 25.3 + 18.1 + 11 + 4.5 = 58.9 · What this means: Earnings are strong; relative strength in its sector is -13.8% and the one-year return is 20.9%. 8. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) AMRX · leader · Evidence leans up · 71% evidence 58.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.0/35 · Revenue 9.3% · Profit 100% · Operating margin change 2.8 points · 83% evidence Capital efficiency 14.8/25 · ROCE 17.1% · Operating margin 18.3% · 76% evidence Valuation 9.3/20 · P/E 35.1× · PEG n/a · 15% evidence Relative strength 13.1/20 · Lead over its industry 14.1% · Lead over S&P 500 27.5% · 1 year 77.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 21 + 14.8 + 9.3 + 13.1 = 58.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 9. [Phibro Animal Health Corporation](https://www.sectoralpha.in/us/stocks/pahc) PAHC · breaking out · Evidence leans up · 81% evidence 58.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.1/35 · Revenue 17.2% · Profit 100% · Operating margin change 0.3 points · 83% evidence Capital efficiency 14.9/25 · ROCE 16.4% · Operating margin 10.6% · 76% evidence Valuation 11.8/20 · P/E 12.8× · PEG 1.44 · 65% evidence Relative strength 7.3/20 · Lead over its industry -22.7% · Lead over S&P 500 -13% · 1 year -14% · 100% evidence · 11 of 12 weeks ahead Exact sum: 24.1 + 14.9 + 11.8 + 7.3 = 58.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [United Therapeutics Corporation](https://www.sectoralpha.in/us/stocks/uthr) UTHR · turning · Evidence leans up · 81% evidence 55.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 14.3/35 · Revenue 2.5% · Profit 5.6% · Operating margin change -6.2 points · 83% evidence Capital efficiency 20.0/25 · ROCE 21.2% · Operating margin 42.2% · 76% evidence Valuation 9.2/20 · P/E 17.5× · PEG 1.92 · 65% evidence Relative strength 11.7/20 · Lead over its industry -2.7% · Lead over S&P 500 9.4% · 1 year 34% · 100% evidence · 3 of 12 weeks ahead Exact sum: 14.3 + 20 + 9.2 + 11.7 = 55.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 11. Liquidia Corporation this page LQDA · quiet · Evidence leans up · 64% evidence 54.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 26.0/35 · Revenue 100% · Profit n/a · Operating margin change 474.2 points · 62% evidence Capital efficiency 17.9/25 · ROCE 50.7% · Operating margin 49.8% · 76% evidence Valuation 9.2/20 · P/E 51.2× · PEG n/a · 15% evidence Relative strength 1.0/20 · Lead over its industry -27.2% · Lead over S&P 500 -18.6% · 1 year 61.7% · 100% evidence · 3 of 12 weeks ahead Exact sum: 26 + 17.9 + 9.2 + 1 = 54.1 · What this means: Earnings are strong; relative strength in its sector is -27.2% and the one-year return is 61.7%. 12. [Viatris Inc.](https://www.sectoralpha.in/us/stocks/vtrs) VTRS · breaking out · Evidence leans up · 64% evidence 52.7 out of 100 Growth Capital Valuation Relative
13. [Trulieve Cannabis Corp.](https://www.sectoralpha.in/us/stocks/trlv) TRLV · breaking out · Evidence leans up · 64% evidence 50.9 out of 100 Growth Capital Valuation Relative
14. [ANI Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/anip) ANIP · basing · Evidence leans up · 64% evidence 50.2 out of 100 Growth Capital Valuation Relative
15. [Teva Pharmaceutical Industries Limited](https://www.sectoralpha.in/us/stocks/teva) TEVA · leader · Evidence leans down · 64% evidence 48.0 out of 100 Growth Capital Valuation Relative
16. [Zoetis Inc.](https://www.sectoralpha.in/us/stocks/zts) ZTS · turning · Evidence leans down · 81% evidence 46.8 out of 100 Growth Capital Valuation Relative
17. [Haleon plc](https://www.sectoralpha.in/us/stocks/hln) HLN · quiet · Too little evidence to rank firmly · 56% evidence 45.8 out of 100 Growth Capital Valuation Relative
18. [Perrigo Company plc](https://www.sectoralpha.in/us/stocks/prgo) PRGO · breaking out · Evidence leans down · 64% evidence 45.1 out of 100 Growth Capital Valuation Relative
19. [Elanco Animal Health Incorporated](https://www.sectoralpha.in/us/stocks/elan) ELAN · turning · Evidence leans down · 71% evidence 43.9 out of 100 Growth Capital Valuation Relative
20. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) LNTH · turning · Evidence leans down · 81% evidence 43.6 out of 100 Growth Capital Valuation Relative
21. [Alkermes plc](https://www.sectoralpha.in/us/stocks/alks) ALKS · quiet · Evidence leans down · 81% evidence 43.4 out of 100 Growth Capital Valuation Relative
22. [HUTCHMED (China) Limited](https://www.sectoralpha.in/us/stocks/hcm) HCM · breaking out · Too little evidence to rank firmly · 51% evidence 39.8 out of 100 Growth Capital Valuation Relative
23. [Prestige Consumer Healthcare Inc.](https://www.sectoralpha.in/us/stocks/pbh) PBH · quiet · Evidence leans down · 71% evidence 35.1 out of 100 Growth Capital Valuation Relative
24. [Alvotech](https://www.sectoralpha.in/us/stocks/alvo) ALVO · breaking out · Most evidence points down · 71% evidence 33.1 out of 100 Growth Capital Valuation Relative
25. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) HIMS · quiet · Most evidence points down · 71% evidence 27.6 out of 100 Growth Capital Valuation Relative
26. [Supernus Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/supn) SUPN · quiet · Most evidence points down · 71% evidence 26.6 out of 100 Growth Capital Valuation Relative
27. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) AMLX · leader · Too little evidence to rank firmly · 40% evidence 48.7 out of 100 Growth Capital Valuation Relative
28. Regencell Bioscience Holdings Limited RGC · breaking out · Too little evidence to rank firmly · 47% evidence 31.8 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led S&P 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led S&P 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Drug Manufacturers - Specialty & Generic](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic), all 28 compared on one page. ## Which companies are close to Liquidia in size? Liquidia is the 15th largest of 51 Drug Manufacturers - Specialty & Generic companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: Amneal Pharmaceuticals, Inc., Lantheus Holdings, Inc. and Hims & Hers Health, Inc. Just below it: Amylyx Pharmaceuticals, Inc., Indivior Pharmaceuticals, Inc. and Bausch Health Companies Inc. ### Drug Manufacturers - Specialty & Generic companies close in size

1. [Amneal Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amrx) $7 billion
2. [Lantheus Holdings, Inc.](https://www.sectoralpha.in/us/stocks/lnth) $6.6 billion
3. [Hims & Hers Health, Inc.](https://www.sectoralpha.in/us/stocks/hims) $6 billion
4. Liquidia Corporation $3.8 billion
5. [Amylyx Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/amlx) $3.7 billion
6. [Indivior Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/indv) $3.3 billion
7. [Bausch Health Companies Inc.](https://www.sectoralpha.in/us/stocks/bhc) $3 billion

[All 51 Drug Manufacturers - Specialty & Generic companies, largest first](https://www.sectoralpha.in/us/sectors/drug-manufacturers-specialty-generic#all-companies)

### Companies close in size in other industries

1. [Madison Square Garden Entertainment Corp.](https://www.sectoralpha.in/us/stocks/msge) $3.8 billion · Entertainment
2. [Mueller Water Products, Inc.](https://www.sectoralpha.in/us/stocks/mwa) $3.8 billion · Specialty Industrial Machinery
3. Liquidia Corporation $3.7 billion
4. [Garrett Motion Inc.](https://www.sectoralpha.in/us/stocks/gtx) $3.7 billion · Auto Parts
5. [Kulicke and Soffa Industries, Inc.](https://www.sectoralpha.in/us/stocks/klic) $3.7 billion · Semiconductor Equipment & Materials

## What else do people ask about Liquidia? ### What were Liquidia's latest quarterly results? Liquidia Corporation reported revenue of ₹0.2 B and net profit of ₹0.1 B for the Jun 2026 quarter. The operating margin was 49.8%, 474.2 percentage points higher than a year earlier (as of 3 November 2026). ### What is Liquidia's market cap? Liquidia Corporation's market capitalisation is $3.8 B at a stock price of $42.20. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Liquidia performing? Liquidia Corporation's share price has been moving sideways for 6 weeks. Over the past 13 weeks it has done worse than the S&P 500, for 9 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Liquidia's stock price go up? This page does not forecast Liquidia Corporation's stock price. What it shows instead: the stock price is $42.20, and it has been moving sideways for 6 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Liquidia in its business cycle? Liquidia Corporation's FY25 operating margin was −32.5%, against a 5-year range of −866.6% to −32.5%: the middle of its own range, neither a peak nor a low. The latest quarter was 49.8%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Liquidia story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Liquidia a stock worth studying right now? What the numbers show: Liquidia Corporation's share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.